Dainippon Sumitomo in option deal for Boston's stem cellness inhibitor
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has acquired an option to Boston Biomedical's BBI608, a novel oral small molecule oncology drug targeting stem cell-like cancer cells. The deal is worth $15 million on signing to the privately held US firm and DSP will also support clinical development activities.